Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients
July 29, 2024 05:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients
DBV Technologies présente ses résultats financiers du premier semestre 2024 et fait le point sur l’évolution de ses activités
July 29, 2024 01:30 ET
|
DBV Technologies S.A.
Châtillon, France, 29 juillet (07:30 CEST), 2024 DBV Technologies présente ses résultats financiers du premier semestre 2024 et fait le point sur l’évolution de ses activités DBV Technologies...
DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024
July 29, 2024 01:30 ET
|
DBV Technologies S.A.
Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq...
Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference
July 28, 2024 17:00 ET
|
Anavex Life Sciences Corp.
Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events Clinical...
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)
July 28, 2024 16:51 ET
|
Longeveron
Longeveron Phase 2a clinical results in Alzheimer's Disease selected for Featured Research oral presentation at Alzheimer’s Association International Conf
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
July 28, 2024 08:05 ET
|
Alector, Inc.
--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- ...
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
July 28, 2024 07:30 ET
|
Acumen Pharmaceuticals, Inc.
NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
LuxUrban Hotels Announces Pricing of Public Offering of Securities
July 26, 2024 20:41 ET
|
LuxUrban Hotels
MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- LuxUrban Hotels Inc. (“LuxUrban” or the “Company”) (Nasdaq: LUXH), which secures long-term operating rights for entire hotels through Master Lease Agreements...
SRIVARU Holding Limited Announces Receipt of Nasdaq Delisting Notification and Plans to Appeal
July 26, 2024 19:41 ET
|
SRIVARU Holding
GRAND CAYMAN, Cayman Islands, July 26, 2024 (GLOBE NEWSWIRE) -- SRIVARU Holding Limited (Nasdaq: SVMH, SVMHW) (“SRIVARU” or the “Company”), a manufacturer of premium electric motorcycles today...
Atlanticus Closes $60 Million Principal Amount of 9.25% Senior Notes Due 2029 in Add-On Offering
July 26, 2024 17:00 ET
|
Atlanticus Holdings Corp
ATLANTA, July 26, 2024 (GLOBE NEWSWIRE) -- Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” “the Company”, “we,” “our” or “us”), a financial technology company that enables its bank,...